Ironwood Pharmaceuticals, Inc.
- IRWD
- NASDAQ
- Drug Manufacturers - Specialty & Generic
- Gastrointestinal (GI) Drugs
- Linaclotide (IBS/Constipation)
$3.56
Today +1.71%Quote Oct 19, 2026, 08:00 PM UTC
−18.35%over the last month
Max drawdown −22.7%From 1-month high −21.4%3 months −9.0%
Our viewPro
The call stays with Pro
Verdict, why now, and the write-up open with Pro. New accounts get 14 days of Pro free.
About Ironwood Pharmaceuticals
Ironwood Pharmaceuticals, Inc. operates as a healthcare enterprise primarily dedicated to discovering, developing, and commercializing therapeutic solutions for gastrointestinal (GI) conditions. Its flagship commercial product is linaclotide, a guanylate cyclase type-C (GC-C) agonist.
Where the money comes from
Q2 2026 revenue $113.0M
- Royalty$1.1M1.0%
- Collaborative Arrangement, Collaboration and License Agreements$397,0000.4%
- Other / not reported$111.5M98.7%
Sector
Healthcare
Industry
Drug Manufacturers - Specialty & Generic
Exchange
NASDAQ
Employees
100
Market value
$588.3M
Quote Oct 19
Floor
$3.53
0.9% below price
Resistance
$3.62
1.6% above price
Price vs analyst targets
30 analysts
Lowest target
$1.00Highest target
$18.00
$1.00Highest target
$18.00
- Price $3.56
- Average target $6.68
- Analysts' target range
Analysts' average target sits about 88% higher. Their range is wide.
The call stays with Pro
7 locked chapters- What to do with this namePro
- Why nowPro
- Why this stockPro
- Section write-upsPro
- Story timelinePro
- News briefPro
- Ask about IRWDPro
Verdict, why now, and the write-up open with Pro. New accounts get 14 days of Pro free.
Log in — 14 days free